Mechanism of Action:
Abemaciclib is a targeted therapy medication that belongs to a class of drugs called cyclin-dependent kinase (CDK) inhibitors.
It specifically inhibits CDK4 and CDK6, which are enzymes involved in regulating the cell cycle.
The cell cycle is the process by which cells grow and divide. CDK4 and CDK6 play a critical role in the progression of the cell cycle, specifically in the G1 phase where cells prepare for DNA replication.
By inhibiting CDK4 and CDK6, abemaciclib disrupts the cell cycle progression and inhibits the growth of cancer cells.
Abemaciclib also has additional effects on other cellular processes, such as promoting tumor cell senescence (cellular aging) and reducing angiogenesis (the formation of new blood vessels that supply tumors).
Indications and Uses:
Abemaciclib is primarily indicated for the treatment of certain types of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
It is used in combination with hormonal therapies, such as aromatase inhibitors, or as a monotherapy in cases of disease progression after prior endocrine therapy.
Abemaciclib is available in the form of oral tablets.
The recommended dosage and treatment schedule may vary depending on the specific indication and the patient's individual factors.
It is typically taken orally, with or without food.
It is important to follow the prescribed dosage instructions provided by the healthcare professional and to take the medication at the same time each day to maintain consistent blood levels.
Common side effects associated with abemaciclib may include:
Diarrhea: Abemaciclib commonly causes diarrhea, which can range from mild to severe. It is important to promptly notify a healthcare professional if diarrhea occurs to manage and treat it appropriately.
Fatigue: Feeling tired or experiencing a lack of energy is a common side effect of abemaciclib. Adequate rest and proper self-care can help manage fatigue.
Other potential side effects that may occur but are less common include nausea, decreased appetite, infections, neutropenia (low white blood cell count), thrombocytopenia (low platelet count), and liver enzyme elevation.
It is essential to report any unusual or severe side effects to a healthcare professional. They can provide guidance on managing side effects and determine if any adjustments or interventions are necessary.
Abemaciclib is a targeted therapy medication used in the treatment of advanced or metastatic breast cancer. It inhibits CDK4 and CDK6 enzymes involved in cell cycle progression, ultimately slowing down the growth of cancer cells.
Abemaciclib is administered orally and may cause side effects such as diarrhea and fatigue.
Individual responses to the medication may vary, and it is important to consult a healthcare professional for personalized information and advice regarding the use of abemaciclib.